Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85696 | 1.00 | DPP4 (0.58) | DPP4DPP8DPP9BLMALOX15 | |
| Hydrochloric Acid SCHEMBL7509758 | 0.98 | DPP4 (0.56) | DPP4DPP8DPP9BLMALOX15 | |
| Hydrochloric Acid SCHEMBL8466590 | 0.98 | DPP4 (0.56) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL86359 | 0.89 | DPP8 (0.47) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL10045874 | 0.83 | DPP4 (0.42) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL24322626 | 0.83 | LMNA (0.41) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL14516431 | 0.83 | LMNA (0.41) | DPP4DPP8DPP9BLMALOX15 | |
| SCHEMBL85942 | 0.83 | GRM8 (0.58) | DPP4DPP8DPP9BLMBMP1 | |
| SCHEMBL24140515 | 0.83 | GRM8 (0.58) | DPP4DPP8DPP9BLMBMP1 | |
| SCHEMBL8763003 | 0.83 | GRM8 (0.58) | DPP4DPP8DPP9BLMBMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-20230357320-A1 | HELICAL STAPLED PEPTIDES AND USES THEREOF | PARABILIS MEDICINES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-RE49569-E1 | Alkylamine derivative | EA PHARMA CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2012010516-A1 | GROWTH HORMONE CONJUGATES | NOVO NORDISK HEALTH CARE AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011089255-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011015649-A1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTH CARE AG (CH) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010029107-A1 | GROWTH HORMONE CONJUGATE WITH INCREASED STABILITY | NOVO NORDISK HEALTH CARE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20070248737-A1 | Process for preparing a tea product | CONOPCO INC, D/B/A UNILEVER | 2007-10-25 | — | — | US | disclosed |
| WO-2007098931-A1 | PROCESS FOR PREPARING A TEA PRODUCT | UNILEVER PLC (GB) | 2007-09-07 | — | — | WO | disclosed |
| EP-0078152-B1 | SALTS OF SULFODEHYDROABIETIC ACID AND TREATMENT OF GASTRO-INTESTINAL DISEASES | Tanabe Seiyaku Co., Ltd. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4529602-A | Sulfodehydroabietic acid compound | TANABE SEIYAKU CO., LTD. (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0078152-A1 | Salts of sulfodehydroabietic acid and treatment of gastro-intestinal diseases | Tanabe Seiyaku Co., Ltd. (JP) | 1983-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357320-A1 | HELICAL STAPLED PEPTIDES AND USES THEREOF | ESRRB, ESR1, ESRRA | DPP4 664/4885DPP8 236/4885DPP9 393/4885 |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP4 649/4885DPP8 427/4885DPP9 438/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | DPP4 649/4885DPP8 427/4885DPP9 438/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP4 649/4885DPP8 427/4885DPP9 438/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | DPP4 649/4885DPP8 427/4885DPP9 438/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | DPP4 649/4885DPP8 427/4885DPP9 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.